

7 Literaturverzeichnis

Abdelrahman AM and Pang CC (2002). "Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats." *Life Sci* 71(7): 819-25.

Ambrus G, Gál P, Kojima M, Szilágyi K, Balczer J, Antal J, Gráf L, Laich A, Moffatt BE, Schwaeble W, Sim RB, Závodszy P et al. (2003). "Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments." *J. Immunol.* 170: 1374–1382.

Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Loudon CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA (1999). "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14." *Nature* 401: 282-286.

Arakawa K (1996). "Serine protease angiotensin II systems." *J Hypertens. Suppl.*, 14(5): 3-7.

Arakawa K and Maruta H (1980). "Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system'." *Nature* 288(5792): 705-6.

Bennett RT, Jones RD, Morice AH, Smith CF, Cowen ME (2004). "Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries." *Thorax.* 59(5):401-7.

Bern HA and Lederis K (1969). "A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts." *J.Endocrinol.* 45 (Suppl.),xi-xii.

Bern HA, Pearson D, Larson BA, Nishioka RS (1985). "Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes." *Recent Prog Horm Res* 41: 533-52.

Bode W (1979). "Activation, activity and inhibition of bovine trypsin." *Naturwissenschaften* 66(5):251-8.

Bohm F and Pernow J (2002). "Urotensin II evokes potent vasoconstriction in humans in vivo." *Br J Pharmacol* 135(1): 25-7.

Boivin S, Guilhaudis L, Milazzo I, Oulyadi H, Davoust D, Fournier A (2006). "Characterization of Urotensin-II Receptor Structural Domains Involved in the Recognition of U-II, URP, and Urantide." *Biochemistry* 45(19): 5993-6002.

Boos CJ and Lip GY (2006). "Is hypertension an inflammatory process?" *Curr Pharm Des* (12): 1623–1635.

Bopst M, Haas C, Car B, Eugster HP (1998). "The combined inactivation of tumor necrosis factor and interleukin-6 prevents induction of the major acute phase proteins by endotoxin." *Eur J Immunol* 28: 4130-4137.

Bottrill FE, Douglas SA, Hiley CR, White R (2000). "Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries." *Br J Pharmacol* 130(8): 1865-70.

Bousette NL, Patel L, Douglas SA, Ohlstein EH, Giaid A (2004). "Increased expression of urotensin II and its cognate receptor GRP14 in atherosclerotic lesions of the human aorta." *Atherosclerosis* 176: 117-123.

Brailoiu E, Brailoiu GC, Miyamoto MD, Dun NJ (2003). "The vasoactive peptide urotensin II stimulates spontaneous release from frog motor nerve terminals." *Br J Pharmacol* 138:1580-1588.

Braun-Menendez E, Fasciolo JC, Leloir LF, Munoz JM (1940). "The substance causing renal hypertension." *J Physiol* 98(3): 283-298.

Brkovic A, Hattenberger A, Kostenis E, Klabunde T, Flohr S, Kurz M, Bourgault S, Fournier A (2003). "Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay." *J Pharmacol Exp Ther* 306(3): 1200-9.

Buerke MD, Prufer D, Dahm M, Oelert H, Meyer J, Darius H (1998). "Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury." *J.Pharmacol. Exp. Ther.* 286: 429–438.

Bunkenborg J, Pilch BJ, Podtelejnikov AV, Wisniewski JR (2004). "Screening for N-glycosylated proteins by liquid chromatography mass spectrometry." *Proteomics* 4(2): 454-65.

Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D (2002). "Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents." *Naunyn Schmiedebergs Arch Pharmacol* 365(2): 141-9.

Camarda V, Spagnol M, Song W, Vergura R, Roth AL, Thompson JP, Rowbotham DJ, Guerrini R, Marzola E, Salvadori S, Cavanni P, Regoli D, Douglas SA, Lambert DG, Calo G (2006). "In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5),DTrp(7),Dab(8)]urotensin II(4-11) (UFP-803)." *Br J Pharmacol* 147(1): 92-100.

Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP (2006). "Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome." *Blood* 108(4): 1267-79.

Chamberlain D, Ullman CG, Perkins SJ (1998). "Possible arrangement of the five domains in human complement factor I as determined by a combination of X-ray and neutron scattering and homology modeling." *Biochemistry* 37(40): 13918-29.

Chen Y, Zhao M, Liu X, Yao W, Yang J, Zhang Z, Tang C (2001). "Urotensin II receptor in the rat airway smooth muscle and its effect on the rat airway smooth muscle cells proliferation." *Chin Med Sci J* 16(4): 231-5.

Cheung BM, Leung R, Man YB, Wong LY (2004). "Plasma concentration of urotensin II is raised in hypertension." *J Hypertens.* 22:1341–1344.

Cohn EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH (1944). "Chemical, clinical, and immunological studies of the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma." *J. Clin. Invest.* 23, 417-432.

Coulouarn Y, Lihmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H (1998). "Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord." *Proc Natl Acad Sci U S A* 95(26): 15803-8.

Crossley LG. (1981). "C3b inactivator and beta1H." *Methods Enzymol.* 80, 112-124.

Crossley LG and Porter RR (1980). "Purification of the human complement control protein C3b inactivator." *Biochem J* 191(1): 173-82.

Davis AE and Alper CA (1984): Factor I (C3b inactivator) the complement regulatory protease. *Methods Enzym. Anal.*, 3rd Ed. (Bergmeyer, H.U., ed.) 5:553-558.

Dschietzig T, Bartsch C, Pregla R, Zurbrugg HR, Armbruster FP, Richter C, Laule M, Romeyke E, Neubert C, Voelter W, Baumann G, Stangl K.(2002). "Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure." *Regul Pept* 110(1): 33-8.

Douglas SA and Ohlstein EH (2000). "Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease." *Trends Cardiovasc Med* 10(6): 229-37.

Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN (2000). "Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey." *Br J Pharmacol* 131(7): 1262-74.

Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A (2002). "Congestive heart failure and expression of myocardial urotensin II." *Lancet* 359(9322): 1990-7.

Dschietzig T, Bartsch C, Pregla R, Zurbrugg HR, Armbruster FP, Richter C, Laule M, Romeyke E, Neubert C, Voelter W, Baumann G, Stangl K (2002). "Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure." *Regul Pept* 110(1): 33-8.

Ebnet K, Vestweber D (1999). "Molecular mechanism that control leukocyte extravasation: the selectines and the chemokines." *Histochem Cell Biol* (112): 1-23.

Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005). "Complement C3 is a risk factor for the development of diabetes: a population-based cohort study." *Diabetes* 54(2):570-5.

Engström G, Hedblad B, Janzon L, Lindgärde F (2006). "Fatality of acute coronary events in relation to hypertension and low-grade inflammation: a population-based cohort study." *J Hum Hypertens* (20): 581–586.

Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T (2002). "Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II." *J Med Chem* 45(9): 1799-805.

Freeman M, Ashkenas J, Rees DJ, Kingsley DM, Copeland NG, Jenkins NA, Krieger M. (1990). "An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors." *Proc Natl Acad Sci U S A* 87(22): 8810-4.

Fremaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH (2004). "Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome." *J Med Genet* 41(6):e84.

Freundenberg N, Kortsik C, Roos A (2002). "Grundlagen der Zytopathologie" Karger, 43-45 (DOI: 10.1159/000066846).

Geelen J, van den Dries K, Roos A, van de Kar N, de Kat Angelino C, Klasen I, Monnens L, van den Heuvel L (2007). "A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome." *Pediatr Nephrol* 22(3):371-5.

Gendron G, Simard B, Gobeil F Jr, Sirois P, D'Orléans-Juste P, Regoli D (2004). "Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats." *Can J Physiol Pharmacol* 82(1):16-21.

Gibson A (1987). "Complex effects on Gillichthys urotensin II on rat aortic strips." *Br J Pharmacol* 91: 205-212.

Goldberger G, Arnaout MA, Aden D, Kay R, Rits M, Colten HR (1984). "Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines." *J Biol Chem* 259(10): 6492-7.

Goldberger G, Bruns GA, Rits M, Edge MD, Kwiatkowski DJ (1987). "Human complement factor I: analysis of cDNA-derived primary structure and assignment of its gene to chromosome 4." *J Biol Chem* 262(21): 10065-71.

Gray GA, Jones MR, Sharif I (2001). "Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition." *Life Sci* 69(2): 175-80.

Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A (2002). "Evidence for a role of mast cells in the evolution to congestive heart failure." *J Exp Med* 195(3): 375-81.

Hassan GS, Douglas SA, Ohlstein EH, Giaid A (2005). "Expression of urotensin-II in human coronary atherosclerosis." *Peptides* (26): 2464–2472.

Hassan GS, Chouiali F, Saito T, Hu F, Douglas SA, Ao Z, Willette RN, Ohlstein EH, Giaid A (2003). "Effect of human urotensin-II infusion on hemodynamics and cardiac function." *Can J Physiol Pharmacol* 81(2): 125-8.

Hauert J, Patston PA, Schapira M (2000): "C1 inhibitor cross-linking by tissue transglutaminase." *J Biol Chem* 275:14558–14562.

Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, McMurray J (2001). "Effects of urotensin II in human arteries and veins of varying caliber." *Circulation* 103(10): 1378-81.

Horn F, Henze C, Heidrich K (2000). "Interleukin-6 signal transduction and lymphocyte function." *Immunobiology* 202: 151-167.

Horstick G, Kempf T, Lauterbach M, Bhakdi S, Kopacz L, Heimann A, Malzahn M, Horstick M, Meyer J, Kempfski O (2001). "C1-esterase-inhibitor treatment at early reperfusion of hemorrhagic shock reduces mesentery leukocyte adhesion and rolling." *Microcirculation* 8:427–433.

Hsiung L, Barclay AN, Brandon MR, Sim E, Porter RR (1982). "Purification of human C3b inactivator by monoclonal-antibody affinity chromatography." *Biochem. J.* 203, 293-298.

Ideishi M, Sasaguri M, Ikeda M, Arakawa K (1990). "Angiotensin-converting activity of tissue kallikrein." *Nephron* 55 Suppl 1: 62-4.

Ishihata A, Ogaki T, Aita T, Katano Y (2005). "Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats." *European Journal of Pharmacology* (523) 119–126.

Itoh H, Itoh Y, Rivier J, Lederis K (1987). "Contraction of major artery segments of rat by fish neuro peptide urotensin II." *Am J Physiol* 252:361–366.

Janeway CA, Travers P, Walport M, Shlomchik M (2002). *Immunologie*. Spektrum Akademischer Verlag 5.Auflage:46-67.

Janeway CA, Travers P, Walport M, Shlomchik M (2005). *Immunobiology*. Garland Science. 6th Edition Figure 2-19.

Jiang H, Wagner E, Zhang H, Frank MM (2001). "Complement 1 inhibitor is a regulator of the alternative complement pathway." *J Exp Med* 194:1609–1616.

Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA (2004). "Urotensin-II-mediated cardiomyocyte hypertrophy:

effect of receptor antagonism and role of inflammatory mediators." *Naunyn Schmiedebergs Arch Pharmacol* 370(4):238-50.

Julen N, Dauchel H, Lemercier C, Sim RB, Fontaine M, Ripoche J (1992). "In vitro biosynthesis of complement factor I by human endothelial cells." *Eur J Immunol* 22(1): 213-7.

Kaidoh T and Gigli I (1989). "Phylogeny of regulatory proteins of the complement system. Isolation and characterization of a C4b/C3b inhibitor and a cofactor from sand bass plasma." *J Immunol* 142(5): 1605-13.

Katano Y, Ishihata A, Aita T, Ogaki T, Horie T (2000). "Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries." *Eur J Pharmacol* 402(1-2):R5-7.

Kavanagh D, Richards A, Atkinson JP (2007). "Complement Regulatory Genes and Hemolytic Uremic Syndromes." *Annu Rev Med*.

Kinney WA, Almond Jr HR, Qi J, Smith CE, Santulli RJ, de Garavilla L, Andrade-Gordon P, Cho DS, Everson AM, Feinstein MA, Leung PA, Maryanoff BE (2002). "Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model." *Angew Chem Int Ed Engl* 41: 2940-2944.

Lachmann PJ (1991). "The control of homologous lysis." *Immunol Today* 12(9): 312-5.

Laine P, Pentikäinen MO, Würzner R, Penttilä A, Paavonen T, Meri S, Kovanen PT (2002). "Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction." *Am J Cardiol* 90(4): 404-8.

Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM, Gilbert RE (2004). "Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy." *Am J Kidney Dis* 44(5): 826-31.

Legoedec J, Gasque P, Jeanne JF, Fontaine M (1995). "Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I." *Eur J Immunol* 25(12):3460-6.

Lehmann C, Birnbaum J, Lührs C, Rückbeil O, Spies C, Ziemer S, Gründling M, Pavlovic D, Usichenko T, Wendt M, Kox WJ (2004). "Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia." *Intensive Care Med* 30: 309–314.

Lehmann TG, Heger M, Munch S, Kirschfink M, Klar E (2000). "In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver." *Transpl Int* 13 (Suppl. 1):547–550.

Lin Y, Tsuchihashi T, Matsumura K, Abe I, Iida M (2003). "Central cardiovascular action of urotensin II in conscious rats." *J Hypertens* 21:159-165.

Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT (1999). "Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14." *Biochem Biophys Res Commun* 266: 174-178.

Lu Y, Zou CJ, Huang DW, Tang CS (2002). "Cardiovascular effects of urotensin II in different brain areas." *Peptides* 23:1631-1635.

MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Pollard K (2000). "Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat." *Br J Pharmacol* 130(2): 201-4.

Maguire JJ and Davenport AP (2002). "Is urotensin-II the new endothelin?" *Br J Pharmacol* 137(5): 579-88.

Maguire JJ, Kuc RE, Davenport AP (2000). "Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1." *Br J Pharmacol* 131(3): 441-6.

Marchese A, Heiber M, Nguyen T, Heng HH, Saldivia VR, Cheng R, Murphy PM, Tsui LC, Shi X, Gregor P (1995). "Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors." *Genomics* 29(2): 335-44.

Matsushita M, Endo Y, Fujita T (2000a). "Cutting edge: complement-activating complex of ficolin and mannosebinding lectin-associated serine protease." *J Immunol* 164:2281-2284.

Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T (2000b). "Proteolytic activities of two types of mannose binding lectin associated serine protease." *J Immunol* 165: 2637-2642.

Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y (2001a). "Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues." *J Hypertens* 19(12): 2185-90.

Matsushita M, Endo Y, Hamasaki N, Fujita T (2001b). "Activation of the lectin complement pathway by ficolins." *Int Immunopharmacol* 1: 359-363.

McMaster D, Kobayashi Y, Rivier J, Lederis K (1986). "Characterization of the biologically and antigenically important regions of urotensin II." *Proc West Pharmacol Soc* 29: 205-208.

Morgan BP and Meri S (1994). "Membrane proteins that protect against complement lysis." *Springer Semin Immunopathol* 15(4): 369-96.

Mori M and Fujino M (2004). "Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain." *Peptides* 25(10): 1815-8.

Muramatsu I, Fujiwara M, Hidaka H, Akutagawa H (1979). "Pharmacological analysis of urotensin-induced contraction and relaxation in isolated rabbit aortas." *Gunma Symp Endocrinol* 16:39–47.

Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti C, Descovich GC, Puddu P (1995). "Association of serum C3 levels with the risk of myocardial infarction." *Am J Med* 98(4):357-64.

Nagasawa S, Ichihara C, Stroud RM (1980). "Cleavage of C4b by C3b inactivator: production of a nicked form of C4b, C4b', as an intermediate cleavage product of C4b by C3b inactivator." *J Immunol* 125, 578-582.

Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE (2002). "Plasma urotensin in human systolic heart failure." *Circulation* 106:2877–2880.

Oksjoki R, Kovanen PT, Pentikainen MO (2003). "Role of complement activation in atherosclerosis." *Curr Opin Lipidol* 14(5): 477-82.

Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M (1993). "Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents." *Jpn J Pharmacol* 62(2): 207-10.

Patacchini R, Santicoli P, Giuliani S, Grieco P, Novellino E, Rovero P, Maggi CA (2003). "Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta." *Br J Pharmacol* 140(7): 1155-8.

Patston PA and Schapira M (1997). "Regulation of C1-inhibitor function by binding to type IV collagen and heparin." *Biochem Biophys Res Commun* 230:597–601.

Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA (1980). "Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes." *Proc Natl Acad Sci U S A* 77(8): 5021-4.

Richards AM and Charles C (2004). "Urotensin II in the cardiovascular system." *Peptides* 25(10): 1795-802.

Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG (2002). "Plasma urotensin II in heart failure." *Lancet* 360(9332):545-6.

Russell FD, Kearns P, Toth I, Molenaar P (2004). "Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro." *J Pharmacol Exp Ther* 310(1): 209-14.

Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG (2002). "Plasma urotensin II in heart failure." *Lancet* 360(9332):545-6.

Rykl J, Thiemann J, Kurzawski S, Pohl T, Gobom J, Zidek W, Schluter H (2006). "Renal cathepsin G and angiotensin II generation." *J Hypertens* 24(9): 1797-807.

Sadallah S, Gudat F, Laissue JA, Spath PJ, Schifferli JA (1999). "Glomerulonephritis in a patient with complement factor I deficiency." *Am J Kidney Dis* 33(6): 1153-7.

Sauzeau V, Le Mellionec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G (2001). "Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase." *Circ Res* 88(11): 1102-4.

Schettler G und Greten H (1998). *Innere Medizin*. Thieme-Verlag 9. Auflage: 221-223.

Schlaf G, Rothermel E, Oppermann M, Schieferdecker HL, Jungermann K, Gotze O (1999). "Rat complement factor I: molecular cloning, sequencing and expression in tissues and isolated cells." *Immunology* 98(3): 464-74.

Schlaf G, Demberg T, Koleva M, Jungermann K, Gotze O (2001). "Complement factor I is upregulated in rat hepatocytes by interleukin-6 but not by interferon-gamma, interleukin-1beta, or tumor necrosis factor-alpha." *Biol Chem* 382(7): 1089-94.

Schlüter H, Jankowski J, Rykl J, Thiemann J, Belgardt S, Zidek W, Wittmann B, Pohl T (2003). "Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system." *Anal Bioanal Chem* 377(7-8): 1102-7.

Schmidt W, Stenzel K, Walther A, Gebhard MM, Martin E, Schmidt H (1999a). "Influence of C1-esterase inhibitor on tissue oxygenation of jejunal mucosa during endotoxemia." *Int J Surg Investig* 1: 277-283.

Schmidt W, Stenzel K, Gebhard MM, Martin E, Schmidt H (1999b). "C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules." *Surgery* 125:280-287.

Schmidt RF, Lang F, Thews G (2005). *Physiologie des Menschen*. Springer Verlag 29.Auflage:639-640.

Shenouda A, Douglas SA, Ohlstein EH, Giaid A (2002). "Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma." *J Histochem Cytochem* 50(7): 885-9.

Sim RB, Reboul A, Arlaud GJ, Villiers CL, Colomb MG (1979). "Interaction of 125I-labelled complement components C1r and C1s with protease inhibitors in plasma." *FEBS Lett* (97): 111-115.

Skeggs LT, Marsh WH, Kahn JR, Shumway NP (1954). "The purification of hypertension I." *J Exp Med* 100(4): 363-70.

Soames CJ and Sim RB (1997). "Interactions between human complement components factor H, factor I and C3b." *Biochem J* 326: 553-561.

Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR (2001). "Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries." *Am J Physiol Heart Circ Physiol* 280(2): H925-8.

Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, Kitada C, Miyajima N, Suzuki N, Mori M, Fujino M (2003). "Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain." *Biochem Biophys Res Commun* 310(3): 860-8.

Szafranska B, Xie S, Green J, Roberts RM (1995). "Porcine pregnancy-associated glycoproteins: new members of the aspartic proteinase gene family expressed in trophoectoderm." *Biol Reprod* 53:21-8.

Takahashi K, Totsune K, Murakami O, Shibahara S (2001). "Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells." *Peptides* 22(7): 1175-9.

Tanner H, Mohacsi P, Fuller-Bicer GA, Rieben R, Meier B, Hess O, Hullin R (2007). "Cytokine activation and disease progression in patients with stable moderate chronic heart failure." *J Heart Lung Transplant* 26(6):622-9.

Thiemann J, Jankowski J, Rykl J, Kurzawski S, Pohl T, Wittmann-Liebold B, Schluter H (2004). "Principle and applications of the protein-purification-parameter screening system." *J Chromatogr A* 1043:73-80.

Thiemann J, (2005). "Suche, Reinigung und Identifizierung von Urotensin-II generierenden Enzyme." Doktorarbeit. FU-Berlin.

Toda N (1987). "Mechanism of histamine action in human coronary arteries." *Circ Res* (61):280-286.

Tostivint H, Joly L, Lihmann I, Parmentier C, Lebon A, Morisson M, Calas A, Ekker M, Vaudry H (2006). "Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families." *Proc Natl Acad Sci U S A* 103(7): 2237-42.

Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, Kikuya M, Ohkubo T, Hashimoto J, Imai Y (2004). "Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy." *Peptides* 25(10): 1809-14.

Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O (2003). "Increased plasma urotensin II levels in patients with diabetes mellitus." *Clin Sci (Lond)* 104(1): 1-5.

Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O (2001). "Role of urotensin II in patients on dialysis." *Lancet* 358(9284): 810-1.

Tsiftoglou SA and Sim RB (2004). "Human complement factor I does not require cofactors for cleavage of synthetic substrates." *J Immunol* 173(1): 367-7.

Tsiftoglou SA, Willis AC, Li P, Chen X, Mitchell DA, Rao Z, Sim RB. (2005). "The catalytically active serine protease domain of human complement factor I." *Biochemistry* 44(16): 6239-49.

Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. (2003). "Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy." *Circ Res* 93(3):246-53.

Urade R, Oda T, Ito H, Moriyama T, Utsumi S, Kito M (1997). "Functions of characteristic Cys-Gly-His-Cys (CGHC) and Gln-Glu-Asp-Leu (QEDL) motifs of microsomal ER-60 protease." *J Biochem (Tokyo)* 122:834-42.

Vergura R, Camarda V, Rizzi A, Spagnol M, Guerrini R, Calo' G, Salvadori S, Regoli D (2004). "Urotensin II stimulates plasma extravasation in mice via UT receptor activation." *Naunyn Schmiedebergs Arch Pharmacol.* 370(5):347-52.

Waldvogel G und Frimmer M (1967). "Untersuchungen zur Lokalisation von Änderungen der Gefäßpermeabilität." *Naunyn-Schmiedebergs Arch Pharmak u exp Path* 258, 321—333.

Wang ZJ, Shi LB, Xiong ZW, Zhang LF, Meng L, Bu DF, Tang CS, Ding WH (2006). "Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout." *Peptides* 27:858-863.

Watanabe T, Pakala R, Katagiri T, Benedict CR (2001a). "Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells." *Circulation* 104(1): 16-8.

Watanabe T, Pakala R, Katagiri T, Benedict CR (2001b). "Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation." *J Hypertens* 19(12): 2191-6.

Watson AM and May CN (2004). "Urotensin II, a novel peptide in central and peripheral cardiovascular control." *Peptides* 25(10): 1759-66.

Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J, Oka Y (2003). "Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects." *Diabetologia* 46(7): 972-6.

Willerson J. T., M.W. Majesky et al. (2001). "Russell Ross, PhD : Visionary Basic Scientist in Cardiovascular Medicine." *Circulation* 103: 478-479.

Wintroub BU, Klickstein LB, Kaempfer CE, Austen KF (1981). "A human neutrophil-dependent pathway for generation of angiotensin II. Purification of the product and identification as angiotensin II." *J Clin Invest* 68(2): 484-90.

Yasojima K, Schwab C, McGeer EG, McGeer PL (2001). "Generation of C-reactive protein and complement components in atherosclerotic plaques." *Am J Pathol* 158(3): 1039-51.

Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z, Du J, Tang C (2002). "Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium." *Heart Vessels* 16(2): 64-8.

Zhu F, Ji L, Luo B (2002). "The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population." *Zhonghua Yi Xue Za Zhi* 82(21): 1473-5.

Ziccardi RJ (1981). "Activation of the early components of the classical complement pathway under physiological conditions." *J Immunol* 126: 1768–1773.

Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, Malatino L (2006). "Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease." *Kidney Int* 69(7):1253-8.